Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF).

This significant research progress has laid a solid foundation for subsequent data collection and analysis. The company expects to announce the key topline data of this trial in the fourth quarter of 2026. The successful completion of this clinical trial marks a critical step forward for Axatilimab in the field of IPF treatment. As an innovative therapy, its research results have attracted much attention from the medical community and are expected to provide new treatment options for patients with idiopathic pulmonary fibrosis.